SpringWorks' Q4 Loss Wider Than Expected, Revenues Beat Estimates

SpringWorks Therapeutics (SWTX) incurred a loss of $1.04 per share in the fourth quarter of 2024, which was wider than the Zacks Consensus Estimate of a loss of 72 cents. The company had reported a loss of$1.44 per share in the year-ago quarter.See the Zacks Earnings Calendar to stay ahead of market-making news.In the fourth quarter, total revenues were $61.5 million, which beat the Zacks Consensus Estimate of$60 million. Total revenues comprised net product sales of Ogsiveo (nirogacestat). The company ge ...